Acyl-CoA synthetases play a pivotal role in fatty acid metabolism, providing activated substrates for fatty acid catabolic and anabolic pathways. Acyl-CoA synthetases comprise numerous proteins with diverse substrate specificities, tissue expression patterns, and subcellular localizations, suggesting that each enzyme directs fatty acids toward a specific metabolic fate.
For purification of the hBG1 C-terminal polyclonal antibody, a maltose binding protein/hBG1 (MBP-hBG1) fusion construct was prepared by excising a 1472 bp EcoRI/XbaI fragment from the hBG1/pcDNA3 clone and transferring it to pMalC2 (New England Biolabs).
The fusion construct, encoding the C-terminal 472 amino acids of hBG1, was then transferred to E. coli strain XL1-blue.
Antibody generation and purification-A peptide corresponding to the C-terminal 15
amino acids of hBG1 was synthesized, conjugated to keyhole limpet hemocyanin, and then us ed to immunize rabbits. These services were performed by a commercial contractor (SigmaGenosys). For affinity purification, MBP-hBG1 fusion protein was expressed in E. coli by induction with isopropyl-ß-D-thiogalactopyranoside. The bacterial pellet was lysed by sonication and proteins were solubilized using 1% Triton X-100. After centrifugation, MBP-hBG1 was found in the insoluble fraction. This insoluble fraction was subjected to preparative SDS-PAGE on a 10% gel to resolve MBP-hBG1 protein from other bacterial proteins. Proteins were blotted onto a nitrocellulose membrane, detected with Ponceau-S, and a strip containing the MBG-hBG1 protein was cut from the membrane. Crude antiserum was diluted with PBS and incubated with In situ hybridization-The method of Giger et al. (14) was used with modification as previously described (15) . Sense and antisense probes corresponding to full-length mBG1 cDNA were prepared and labeled with digoxigenin as previously described (15) .
Indirect immunofluorescence and immunohistochemistry-For indirect
immunofluorescence analysis, cells were fixed in 4% formaldehyde in phosphate-buffered saline and permeabilized with 1.0 % Triton X-100 prior to incubation with primary and secondary antibodies as described previously (16) . For immunohistochemistry, tissues from 3 mont h-old mice were harvested, quickly frozen in liquid nitrogen, and stored at -80 o C. Tissue sections were cut using a cryostat and fixed with 4% paraformaldehyde as described previously (15) . Brain 8 rabbit antibody (affinity purified anti-peptide antibody, 1:100) was for 1 h at 37 o C or overnight at 4 o C. Peroxidase-based detection was done using a Vectastain ABC kit (Vector Laboratories).
After counterstaining with Hematoxylin-Harris stain for 30 sec, sections were dehydrated and mounted with DPX mounting solution (Fluka Biochemika).
Acyl-CoA synthetase and fatty acid ? -oxidation assays-Acyl-CoA synthetase assays utilizing radiolabeled substrates and fatty acid ? -oxidation studies of labeled palmitic and lignoceric acids were performed as previously described (17, 18) . The fluorometric assay of acyl-
CoA synthetase activity was a coupled assay in which the acyl-CoA product was subsequently oxidized by acyl-CoA oxidase; H 2 O 2 generated in the latter reaction was quantitated using a modification of the method of Guilbault et al. (19) . Each reaction tube contained, in a total volume of 250 ? l, 10 nmol of unlabeled fatty acid (solubilized with ? -cyclodextrin (18) was prepared by PCR amplification of a 450 bp fragment using 5'-AGAGTCTCCAAGTCACGGTC-3' and 5'-GGTGTAGATGCCAGTGACAAT-3' as forward and reverse primers, respectively, and mouse brain cDNA as template. For control, a 528 bp glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was similarly prepared using 5'-ACCACCATGGAGAAGGCTGG-3' and 5'-CTCAGTGTAGCCCAGGATGC-3' as forward and reverse primers, respectively. Conditions for probe labeling, hybridization, and detection were as previously described (20) . A human multiple tissue expression membrane containing 76 tissues was obtained from Clontech. A cDNA probe for detection of hBG1 mRNA was prepared by PCR amplification of a 1138 bp fragment using 5'-CACGATGGAGGAATTCATGG-3' and 5'-CACTCTGACCAGACTGATA-3' as forward and reverse primers, respectively, and hBG1 cDNA (5) as template.
Subcellular fractionation-Neuro2a cells and mouse tissues were fractionated essentially as described by de Duve et al. (21) . Three confluent 10cm dishes of Neuro2a cells were harvested by gentle trypsinization, washed with phosphate-buffered saline, and resuspended in 1.3 ml ice-cold homogenization buffer (0.25 M sucrose, 10 mM Tris (Cl -), pH 8.0, 1 mM EDTA, and protease inhibitor cocktail (Roche)), and disrupted on ice using three passes through a precision ball-bearing homogenizer (22) . Mouse tissue (brain or liver) were homogenized in 5 vols of the same buffer with a motor-driven Potter-Elvehjem homogenizer (3 passes).
Homogenates were centrifuged (4 o C) for 30 sec at 1500 x g to pellet nuclei (N). The post-nuclear supernatant was centrifuged for 15 min at 3500 x g to sediment a crude mitochondrial fraction (M). The post-mitochondrial supernatant was centrifuged for 10 min at 18,000 x g to obtain the peroxisome-enriched "light mitochondrial" fraction (L). The resulting supernatant was then centrifuged for 15 min at 435,000 x g to obtain a microsomal pellet (P) and a cytosolic supernatant (S). In some experiments, the crude mitochondrial fraction was further separated into a purified mitochondrial fraction and the mitochondria-associated membrane (MAM) fraction by centrifugation through a Percoll gradient as described by Vance and coworkers (23, 24) . were transfected with a mixture of the three mBG1-specific siRNAs or the mSA-specific siRNA using the siPORT Amine reagent (Ambion). Briefly, 30 ? l siPORT Amine was mixed with 560
? l OptiMEM (Invitrogen) and incubated for 15 min at room temperature. siRNAs were added to a final concentration of 50 nM and the incubation was continued for 10 min. This mixture was then added at a final concentration of 5 nM to cells in 2.4 ml OptiMEM. After incubation for 16 h at 37 o C in the cell culture incubator, 7 ml of usual culture medium (DMEM containing 10% fetal bovine serum) was added and incubation at 37 o C was continued for up to 6 days.
RESULTS

Substrate specificity of hBG1 expressed in COS-1 cells-COS-1 cells were transiently
transfected with hBG1 cDNA and the increase in cellular ACS activity due to expression of hBG1 protein was measured. We previously demonstrated that hBG1 had both LACS and VLACS activity using, respectively, radiolabeled palmitic acid (C16:0) and lignoceric acid (C24:0) substrates (5) . To extend our knowledge of the substrate specificity of this enzyme, we examined the ACS activity toward several saturated, monounsaturated, and polyunsaturated fatty acids using a coupled fluorometric assay. Compared to vector-transfected control COS-1 cells, hBG1-expressing cells activated several saturated fatty acids (C14:0, C16:0, and C18:0), the ? 9 monounsaturated fatty acids oleic (C18:1), erucic (C22:1), and nervonic (C24:1), the ? 6 polyunsaturated fatty acids linoleic (C18:2) and arachidonic (C20:4), and the ? 3 polyunsaturated fatty acids ? -linolenic (C18:3), eicosapentaenoic (C20:5), and docosahexaenoic (C22:6) ( Fig. 1 ).
In contrast, hBG1 failed to activate either the ? -methyl branched-chain fatty acid phytanic acid or the ? -methyl branched-chain fatty acid pristanic acid (data not shown). Thus, when overexpressed in COS-1 cells, hBG1 appears to have a diverse substrate specificity and is able to activate a broad spectrum of unbranched fatty acids. The fluorometric assay was not sensitive enough to detect activation of lignoceric acid (data not shown).
Identification of cell types endogenously expressing mBG1-Previously, using a human multiple-tissue Northern blot containing only 8 different tissues, we reported tha t hBG1 was expressed primarily in brain (5) . Subsequently, Moriya-Sato et al. reported that in the mouse, BG1 was expressed in adrenal gland and testis as well (7), and Tang et al. noted that rat BG1 was also expressed in ovary (8) . A Northern blot prepared using total RNA from tissues of three month-old 129SvEv mice and probed with an mBG1-specific probe indicated that mBG1 was expressed in brain, adrenal gland, testis, ovary, and spleen ( Fig. 2A ). An RNA dot blot representing 76 different human tissues was also examined with an hBG1-specific antisense probe ( Fig 2B) . All regions of human brain except pituitary gland highly expressed hBG1.
Modest expression was detected in human testis and adrenal gland, but hBG1 message was not very abundant in ovary or spleen
To investigate the normal metabolic role of BG1, we first needed to identify the specific cell types within these tissues that express the protein.
In situ hybridization of mouse tissues using a mBG1-specific antisense probe suggested that in brain, neurons were the primary cells expressing mBG1 mRNA. Neuronal expression was particularly evident in cortical neurons, granule cells of the dentate gyrus, and pyramidal cells of hippocampus ( and 3K&L for cortex, hypothalamus, and cerebellum, respectively). In the adrenal gland, mBG1 mRNA was detected in both the cortex and the medulla (Fig 3M) , and higher magnification revealed significant staining in the zona fasciculata of the cortex (Fig. 3N ). Histochemical staining detected mBG1 protein primarily in zona fasciculata cells of the cortex; no significant staining of the adrenal medulla was observed (Fig. 3O&P ). In the mouse testis, interstitial Leydig cells were found to highly express mBG1 mRNA ( Based on the observations that mBG1-containing vesicles were observed in close proximity to mitochondria and that mBG1 immunoreactivity was found primarily in the Mfraction, we hypothesized that BG1 might be present in the mitochondria-associated membrane (MAM) fraction. The crude mitochondrial fraction was separated into purified mitochondrial and MAM fractions as described under Experimental Procedures (23, 24) . BG1 remained associated with purified mitochondria in both Neuro2a cell and mouse brain preparations (Fig. 5B) , whereas the liver-specific marker for MAM, phosphatidylethanolamine N-methyltransferase 2 (PEMT), was found in the MAM and P-fraction.
RNA interference decreases mBG1 expression in Neuro2a cells-Initial attempts to
elucidate the role of mBG1 in normal cellular fatty acid metabolism by overexpressing the enzyme in COS-1 cells were unsuccessful. Although we clearly demonstrated using this system that hBG1 is a robust ACS capable of activating a wide range of long-to very long-chain fatty acids ( Fig. 1 ) and (5), no effect on downstream processes such as fatty acid ? -oxidation (5) or incorporation into complex lipids (data not shown) was observed. We hypothesized that unless fatty acid activation was the rate-limiting step in any of these processes, overexpression studies would not provide an answer. Therefore, we used RNA interference to examine the effect of lowering mBG1 expression in cells that endogenously express the protein. Neuro2a cells were transfected with mBG1-specific siRNA as described in Experimental Procedures and examined for mBG1 expression by indirect immunofluorescence daily for six days post-transfection.
Compared to non-transfected cells (day 0), we observed a time-dependent decrease in mBG1 expression that peaked 3-4 days following transfection (Fig. 6A) . Control siRNA specific for mouse serum albumin had no effect on mBG1 expression. After 5-6 days in culture, resumption of mBG1 expression was evident.
The decrease in mBG1 expression in Neuro2a cells transfected with mBG1-specific siRNA was confirmed by Western blot analysis performed on Neuro2a cells three days posttransfection. Both non-transfected (Fig 6B, lane a) and control transfected (mSA siRNA; Fig.   6B , lane b) cells had detectable mBG1 protein, whereas this protein was not detectable in cells transfected with mBG1 siRNA (Fig. 6B, lane c) . In contrast, the mitochondrial protein Mn superoxide dismutase (Mn SOD) was detected in control, mSA siRNA-transfected, and mBG1-transfected Neuro2a cells (Fig. 6C , lanes a, b, and c, respectively). Thus, Western blot results are in agreement with those obtained using immunofluorescence.
Acyl-CoA synthetase activity in Neuro2a cells following downmodulation of mBG1
expression-To verify that mBG1-siRNA treatment of Neuro2a cells decreased enzyme activity as well as protein levels, we measured total cellular acyl-CoA synthetase activity using LCFA and VLCFA substrates. Neuro2a cells transfected with mBG1-specific siRNA showed a 35 % decrease in activation of the LCFA, C16:0 (Fig. 7A ), but only a 10 % decrease in VLCFA (C24:0) activation (Fig. 7B) . No effect of transfection with control (mouse serum albumin) siRNA was observed. The decrease in C16:0 activation by mBG1-specific siRNA was statistically significant (p<0.0001, mBG1 vs. mSA) whereas the decrease in C24:0 activation was not (p=0.19, mBG1 vs. mSA).
Overexpression studies indicated that hBG1 activated a wide range of fatty acids (Fig. 1) .
Therefore, we measured acyl-CoA synthetase activity in siRNA-treated Neuro2a cells using several substrates that showed high activity in overexpressing cells. We observed decreased activation of C14:0 and C18:0 in mBG1 siRNA-treated Neuro2a cells (Fig. 8) , although the magnitude of decrease was not as great as that observed with C16:0. There was no apparent decrease in the activation of C18:1? 9, C18:2? 6, C20:4? 6, or C22:6? 3 in mBG1 siRNA-treated Neuro2a cells (Fig. 8) . A generally applicable approach to the elucidation of biological function of an ACS is to determine its tissue and/or cellular expression pattern, to identify its subcellular location, and to examine its fatty acid substrate specificity. A human multiple tissue Northern blot containing eight tissues revealed that hBG1 was highly expressed in the brain (5). Analysis of a human RNA dot blot containing 76 different tissues or tissue regions confirmed the high expression in brain, with moderate expression also seen in adrenal gland and testis (Fig. 2) . In mouse tissues, ovary and spleen had significant mBG1 expression as well as brain, testis and adrenal gland. We were unable to detect significant ACS activity in high-speed supernatants of mouse brain using either LCFA or VLCFA substrates, casting doubt that the subcellular localization of hBG1 in transiently transfected cell accurately represented its endogenous location. Therefore, it was critical to establish not only the tissue expression pattern, but also the specific cell types that expressed BG1. Both in situ hybridization and immunohistochemical studies indicated that endogenous mBG1 is present primarily in neurons and in steroidogenic cells of the adrenal gland, testis, and ovary (Fig. 3) . We therefore obtained cell lines derived from neurons (Neuro2a), adrenocortical cells (Y-1), and testicular Leydig cells (MA-10) and found that they expressed endogenous BG1. In contrast to the results of hBG1 overexpression studies, endogenous mBG1 was found in punctate vesicles in these cells and not in the cytoplasm.
Interestingly, hBG1 with or without a myc-epitope tag at its N-terminus was cytoplasmic when transiently expressed in Neuro2a cells (data not shown).
The vesicles in which mBG1 was found in Neuro2a cells appeared to be associated with mitochondria, both by morphological appearance (Fig. 4) and by sedimentation during differential centrifugation (Fig. 5A ). Vance and colleagues have isolated from rat liver a mitochondria-associated membrane (MAM) fraction involved in phospholipid biosynthesis (23) .
We hypothesized that the BG1-containing vesicles might be MAM and obtained purified mitochondria and MAM from Neuro2a cells, mouse brain and mouse liver. While BG1 remained associated with purified mitochondria in Neuro2a cells and brain, the liver-specific MAM marker, phosphatidylethanolamine N-methyltransferase 2 (23,27,28), was clearly evident in liver MAM (Fig. 5B ). Since brain lacks phosphatidylethanolamine N-methyltransferase (27) , and liver does not express BG1, it is difficult to establish conclusively that mBG1-containing vesicles are not MAM. Other approaches such as immuno-electron microscopy may be necessary to resolve this issue.
Earlier work clearly established that, when overexpressed in COS-1 cells, hBG1 is an ACS capable of activating both LCFA and VLCFA (5) . Further analysis presented here demonstrates that overexpressed hBG1 can activate a wide range of diverse fatty acid substrates, including saturated, monounsaturated, and polyunsaturated fatty acids. In contrast, RNA interference studies using siRNA specific for mBG1 in Neuro2a cells clearly demonstrated that the substrate preference of the endogenous enzyme is highly specific for the LCFA, palmitic acid (C16:0). Several fatty acids that appeared to be excellent substrates for the overexpressed enzyme do not appear to be good substrates for endogenous BG1. The most likely explanation for these observations is that the soluble overexpressed form of BG1 is in a more relaxed conformation than the vesicle-bound endogenous enzyme, decreasing selectivity at the substrate binding site.
RNA interference studies in Neuro2a cells produced several additional important results.
First, these studies confirmed that the anti-peptide antibody was specific for BG1 on the basis of immunofluorescence and Western blot studies (Fig. 6) . Second, they confirmed that endogenous mBG1 has ACS activity (Fig. 7) . Third, siRNA results indicated that mBG1 accounts for about one-third of the total cellular C16:0-CoA synthetase activity in Neuro2a cells. Significant residual activity is not surprising since brain is known to express other enzymes capable of activating LCFA, notably ACS2 and ACS3 (29, 30) . Fourth, these studies suggested that mBG1 channels its products, long-chain fatty acyl-CoAs, at least in part, to mitochondrial ? -oxidation (Fig. 7) . This finding is consistent with the observation that mBG1-containing vesicles are in close proximity to mitochondria and that these vesicles co-sediment with mitochondria.
However, it is clear that mBG1 is not the only enzyme with LACS activity that provides activated fatty acids for ? -oxidation. Fifth, these results indicated that despite the ability of hBG1 or mBG1 to activate VLCFA when overexpressed in COS-1 cells, mBG1 does not contribute significantly to overall VLCFA metabolism in Neuro2a cells.
The lack of a substantive decrease in total cellular VLACS activity by mBG1-specific RNA interference further implies tha t that there are other enzymes with VLACS activity in Neuro2a cells. Several enzymes belonging to the VLACS family of ACSs are candidates for this role. The first identified enzyme of this family (known as VLCS, VLACS, FACVL1, and FATP2) can activate VLCFA substrates, but is not highly expressed in brain (13, (31) (32) (33) (34) have VLACS activity, and in contrast to VLCS and BG1, prefer VLCFA to LCFA substrates (35, 36) . For in situ hybridization studies, results shown were obtained with a digoxigenin-labeled mBG1
antisense probe, prepared as described previously (15); cells expressing mBG1 are stained blue.
No signal was detected us ing the corresponding sense probe (data not shown). For histochemical studies, polyclonal antibody raised against the C-terminal 15 amino acids of hBG1 was used.
Immunoreactive cells are stained brown, while the blue counterstain highlights non-reactive Fractions were subjected to SDS-PAGE and Western blotting using antibodies to BG1 (~75 kDa), the mitochondrial protein Mn superoxide dismutase (MnSOD; 26 kDa), or the peroxisomal membrane protein Pex13p (35 kDa). B) Crude mitochondria (M (Cr))) fractions from Neuro2a cells, mouse brain, and mouse liver were subjected to density gradient centrifugation on Percoll to yield purified mitochondria (M (P)) and the mitochondria-associated membrane (MAM)
fraction. Western blots of these fractions, along with the microsomal (P) fraction, were analyzed using antibodies to BG1 or the liver-specific MAM marker phosphatidylethanolamine Nmethyltransferase 2 (~20 kDa; PEMT). 
